A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.

MLA

Gatti-Mays, Margaret E., et al. “A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.” The Oncologist, vol. 25, no. 12, Dec. 2020, p. 1013. EBSCOhost, https://doi.org/10.1634/theoncologist.2020-0491.

APA

Gatti-Mays, M. E., Karzai, F. H., Soltani, S. N., Zimmer, A., Green, J. E., Lee, M.-J., Trepel, J. B., Yuno, A., Lipkowitz, S., Nair, J., McCoy, A., & Lee, J.-M. (2020). A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. The Oncologist, 25(12), 1013. https://doi.org/10.1634/theoncologist.2020-0491

Chicago

Gatti-Mays, Margaret E, Fatima H Karzai, Sanaz N Soltani, Alexandra Zimmer, Jeffrey E Green, Min-Jung Lee, Jane B Trepel, et al. 2020. “A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.” The Oncologist 25 (12): 1013. doi:10.1634/theoncologist.2020-0491.